Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Volpara narrows full year net loss, contract value increases

Monday 29 May 2017 01:25 PM

Volpara narrows full year net loss, contract value increases

By Rebecca Howard

May 29 (BusinessDesk) - Volpara Health Technologies, the Wellington-based, ASX-listed digital health company, narrowed its annual loss and said year-on-year growth, in terms of total contract value, continues to accelerate.

Volpara reported a net loss of $9.6 million in year to March 31 versus $30.4 million in the prior year or a loss of 7 cents per share versus a loss of $1.08 per share, it said. The prior year's result was impacted by a $24.6 loss on fair value revaluation of convertible preference shares.

The company, which is focused on early detection of breast cancer, said it began the 2018 financial year with an annual recurring revenue, or ARR, of $1.1 million versus $160,000 at the beginning of the prior year. ARR is the contracted revenue expected to be booked over the next 12 months from current contracts alone. This year, it expects strong annual recurring revenue growth in excess of 200 percent.

Its total contract value, which includes capital sales, service maintenance agreements and Software-as-a-Service contracts, was $4.1 million in the year to March 31, up from $2.8 million in the prior year, the company said.

The move to a SaaS revenue model and the cloud has been "well received" by customers, it said, noting that since the first sale of its VolparaEnterprise software less than a year ago its customers have processed more than 530,000 images using the software and the numbers continue to grow. In the US alone it captured around 1 percent of women screened annually, or some 400,000 women, and by the end of the current financial year it expects that will increase to 3 percent.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

However, revenues lagged its contracted sales, it said. Revenue and grant income was $2 million, down from $2.6 million in the prior year. Operating expenses were $10.9 million versus $6.5 million in the prior 12 months. Product development expenditure increased due to investment in cloud infrastructure and the VolparaEnterprise software.

"During FY17 we made essential investments in our product offering and team, which will provide the platform for future growth," said chief executive Ralph Highnam.

Volpara first listed on the ASX in April last year, having raised about A$10 million selling shares at 50 Australian cents each. It raised a further A$10 million at 60 Australian cents a share late last year. It currently has a cash position - including cash, cash equivalents and cash on deposit - of $12.9 million.

The shares fell 2.8 percent to 35 Australian cents, having dropped 43 percent so far this year.

(BusinessDesk)

ends

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.